{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:41:23Z","timestamp":1794962483276,"version":"4.9.1"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"2020 double talents of Maoming People's Hospital","award":["SY2020004"],"award-info":[{"award-number":["SY2020004"]}]},{"name":"2022 Zhanjiang City science and technology plan project","award":["220825234544746"],"award-info":[{"award-number":["220825234544746"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ovarian cancer is a lethal disease with high mortality due to late diagnosis, recurrence, and chemotherapy resistance. There is an urgent need for better diagnostic and therapeutic strategies. Recently, protein post-translational modifications (PTMs) have gained significant attention for their role in the onset, progression, and treatment of ovarian cancer. PTMs (including phosphorylation, ubiquitination, methylation, ADP-ribosylation, and others) significantly influence tumor cell proliferation, metastasis, and drug resistance by modulating cellular signal transduction, DNA repair mechanisms, and metabolic processes. PARP inhibitors block the active site of PARP1 in\n                    <jats:italic>BRCA<\/jats:italic>\n                    -mutant ovarian cancer, disrupting ADP-ribosylation, inducing apoptosis in cancer cells, and extending progression-free survival. However, the emergence of drug resistance, such as\n                    <jats:italic>BRCA<\/jats:italic>\n                    reversal mutations, and the insufficient specificity of targets remain significant limitations to therapeutic efficacy. Strategies targeting other modification pathways, such as ubiquitination and methylation, provide promising options for expanding treatments. Combination therapies, like integrating PARP inhibitors with chemotherapy or immunotherapy, and precision medicine also show potential to overcome therapeutic challenges. This article systematically examines the pivotal role of PTMs in ovarian cancer pathogenesis, outlines therapeutic strategies and associated challenges in targeting PTMs, and offers a comprehensive overview with strategic guidance for future research.\n                  <\/jats:p>","DOI":"10.1186\/s13048-025-01833-w","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:22:53Z","timestamp":1762874573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic targeting of post-translational modifications in ovarian cancer: mechanisms and clinical applications"],"prefix":"10.1186","volume":"18","author":[{"given":"Ling","family":"Ke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"1833_CR1","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.2147\/IJN.S257527","volume":"15","author":"J Xue","year":"2020","unstructured":"Xue J, Li R, Gao D, Chen F, Xie H. CXCL12\/CXCR4 Axis-Targeted Dual-Functional Nano-Drug delivery system against ovarian cancer. Int J Nanomed. 2020;15:5701\u201318.","journal-title":"Int J Nanomed"},{"key":"1833_CR2","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.3390\/cancers14092262","volume":"14","author":"S Sah","year":"2022","unstructured":"Sah S, Ma X, Botros A, Gaul DA, Yun SR, Park EY, et al. Space- and Time-Resolved metabolomics of a High-Grade serous ovarian cancer mouse model. Cancers (Basel). 2022;14:2262.","journal-title":"Cancers (Basel)"},{"key":"1833_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41419-022-04756-2","volume":"13","author":"Z Lu","year":"2022","unstructured":"Lu Z, Yuan S, Ruan L, Tu Z, Liu H. Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial-mesenchymal transition via integrin \u03b21-ILK-SNAIL1 pathway in ovarian cancer. Cell Death Dis. 2022;13:304.","journal-title":"Cell Death Dis"},{"key":"1833_CR4","doi-asserted-by":"publisher","first-page":"e2202260","DOI":"10.1002\/advs.202202260","volume":"9","author":"Y Hua","year":"2022","unstructured":"Hua Y, Yin H, Liu X, Xie J, Zhan W, Liang G, et al. Salt-Inducible kinase 2-Triggered release of its inhibitor from hydrogel to suppress ovarian cancer metastasis. Adv Sci (Weinh). 2022;9:e2202260.","journal-title":"Adv Sci (Weinh)"},{"key":"1833_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3892\/ijo.2022.5340","volume":"60","author":"R Zhang","year":"2022","unstructured":"Zhang R, Roque DM, Reader J, Lin J. Combined Inhibition of IL\u20136 and IL\u20138 pathways suppresses ovarian cancer cell viability and migration and tumor growth. Int J Oncol. 2022;60:50.","journal-title":"Int J Oncol"},{"key":"1833_CR6","doi-asserted-by":"publisher","first-page":"D874","DOI":"10.1093\/nar\/gky821","volume":"47","author":"Y Yang","year":"2019","unstructured":"Yang Y, Peng X, Ying P, Tian J, Li J, Ke J, et al. AWESOME: a database of SNPs that affect protein post-translational modifications. Nucleic Acids Res. 2019;47:D874\u201380.","journal-title":"Nucleic Acids Res"},{"key":"1833_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3390\/jcm8050691","volume":"8","author":"B Ura","year":"2019","unstructured":"Ura B, Monasta L, Arrigoni G, Battisti I, Licastro D, Di Lorenzo G, et al. Phosphoproteins involved in the Inhibition of apoptosis and in cell survival in the leiomyoma. J Clin Med. 2019;8:691.","journal-title":"J Clin Med"},{"key":"1833_CR8","doi-asserted-by":"publisher","first-page":"jcs243766","DOI":"10.1242\/jcs.243766","volume":"133","author":"S Khondker","year":"2020","unstructured":"Khondker S, Kajjo S, Chandler-Brown D, Skotheim J, Rudner A, Ikui A. PP2ACdc55 dephosphorylates Pds1 and inhibits spindle elongation in S. cerevisiae. J Cell Sci. 2020;133:jcs243766.","journal-title":"J Cell Sci"},{"key":"1833_CR9","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41419-021-03720-w","volume":"12","author":"L Wu","year":"2021","unstructured":"Wu L, Kou F, Ji Z, Li B, Zhang B, Guo Y, et al. SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7. Cell Death Dis. 2021;12:439.","journal-title":"Cell Death Dis"},{"key":"1833_CR10","doi-asserted-by":"crossref","unstructured":"Yan J, Deng X, ling, Ma S qi, hui Li Y, Gao Y, min, Shi G et al. tao,. Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2\/H3K27me3-dependent cell cycle progression and antitumour immune response. BMC Complement Med Ther. 2023;23:160.","DOI":"10.1186\/s12906-023-03975-0"},{"key":"1833_CR11","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1093\/nar\/gkaa130","volume":"48","author":"H-Y Liu","year":"2020","unstructured":"Liu H-Y, Liu Y-Y, Yang F, Zhang L, Zhang F-L, Hu X, et al. Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer. Nucleic Acids Res. 2020;48:3638\u201356.","journal-title":"Nucleic Acids Res"},{"key":"1833_CR12","doi-asserted-by":"publisher","first-page":"2001364","DOI":"10.1002\/advs.202001364","volume":"7","author":"L Zhang","year":"2020","unstructured":"Zhang L, Yang J, Luo Y, Liu F, Yuan Y, Zhuang S. A p53\/lnc-Ip53 negative feedback loop regulates tumor growth and chemoresistance. Adv Sci (Weinh). 2020;7:2001364.","journal-title":"Adv Sci (Weinh)"},{"key":"1833_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/nar\/gkad1119","volume":"52","author":"K Zhu","year":"2023","unstructured":"Zhu K, Suskiewicz MJ, Chatrin C, Str\u00f8mland \u00d8, Dorsey BW, Aucagne V, et al. DELTEX E3 ligases ubiquitylate ADP-ribosyl modification on nucleic acids. Nucleic Acids Res. 2023;52:801\u201315.","journal-title":"Nucleic Acids Res"},{"key":"1833_CR14","doi-asserted-by":"crossref","unstructured":"Lu Z, Mao W, Yang H, Santiago-O\u2019Farrill JM, Rask PJ, Mondal J, et al. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. J Clin Invest. 2022;132:e146471.","DOI":"10.1172\/JCI146471"},{"key":"1833_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-020-01262-x","volume":"19","author":"T Sun","year":"2020","unstructured":"Sun T, Liu Z, Yang Q. The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer. 2020;19:146.","journal-title":"Mol Cancer"},{"key":"1833_CR16","doi-asserted-by":"publisher","first-page":"e750","DOI":"10.3399\/bjgp18X699533","volume":"68","author":"CW Helsper","year":"2018","unstructured":"Helsper CW, Van Vliet LM, Velthuizen ME, de Wit NJ, Beijaert RP, Butter E, et al. Identifying patients with a history of ovarian cancer for referral for genetic counselling: non-randomised comparison of two case-finding strategies in primary care. Br J Gen Pract. 2018;68:e750\u20136.","journal-title":"Br J Gen Pract"},{"key":"1833_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-019-0725-6","volume":"12","author":"ZS Lima","year":"2019","unstructured":"Lima ZS, Ghadamzadeh M, Arashloo FT, Amjad G, Ebadi MR, Younesi L. Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. J Hematol Oncol. 2019;12:38.","journal-title":"J Hematol Oncol"},{"key":"1833_CR18","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1053\/j.gastro.2020.03.086","volume":"159","author":"SS Kupfer","year":"2020","unstructured":"Kupfer SS, Gupta S, Weitzel JN, Samadder J. AGA clinical practice update on colorectal and pancreatic cancer risk and screening in BRCA1 and BRCA2 carriers: commentary. Gastroenterology. 2020;159:760\u20134.","journal-title":"Gastroenterology"},{"key":"1833_CR19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13045-019-0700-2","volume":"12","author":"M Li","year":"2019","unstructured":"Li M, Li A, Zhou S, Lv H, Yang W. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer. J Hematol Oncol. 2019;12:14.","journal-title":"J Hematol Oncol"},{"key":"1833_CR20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41467-019-08530-5","volume":"10","author":"C Bian","year":"2019","unstructured":"Bian C, Zhang C, Luo T, Vyas A, Chen S-H, Liu C, et al. NADP\u2009+\u2009is an endogenous PARP inhibitor in DNA damage response and tumor suppression. Nat Commun. 2019;10:693.","journal-title":"Nat Commun"},{"key":"1833_CR21","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3390\/cancers14061494","volume":"14","author":"S Hesse-Biber","year":"2022","unstructured":"Hesse-Biber S, Seven M, Jiang J, Schaik SV, Dwyer AA. Impact of BRCA status on reproductive Decision-Making and Self-Concept: A Mixed-Methods study informing the development of tailored interventions. Cancers (Basel). 2022;14:1494.","journal-title":"Cancers (Basel)"},{"key":"1833_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ygyno.2015.12.017","volume":"140","author":"SS Bernards","year":"2016","unstructured":"Bernards SS, Norquist BM, Harrell MI, Agnew KJ, Lee MK, Walsh T, et al. Genetic characterization of early onset ovarian carcinoma. Gynecol Oncol. 2016;140:221\u20135.","journal-title":"Gynecol Oncol"},{"key":"1833_CR23","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41375-020-01095-z","volume":"35","author":"TT Vu","year":"2021","unstructured":"Vu TT, St\u00f6lzel F, Wang KW, R\u00f6llig C, Tursky ML, Molloy TJ, et al. miR-10a as a therapeutic target and predictive biomarker for MDM2 Inhibition in acute myeloid leukemia. Leukemia. 2021;35:1933\u201348.","journal-title":"Leukemia"},{"key":"1833_CR24","doi-asserted-by":"publisher","first-page":"10983","DOI":"10.3390\/ijms222010983","volume":"22","author":"MA Sharpe","year":"2021","unstructured":"Sharpe MA, Baskin DS, Jenson AV, Baskin AM. Hijacking sexual Immuno-Privilege in GBM\u2014An Immuno-Evasion strategy. Int J Mol Sci. 2021;22:10983.","journal-title":"Int J Mol Sci"},{"key":"1833_CR25","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3390\/ijms17081285","volume":"17","author":"Y-F Hou","year":"2016","unstructured":"Hou Y-F, Gao S-H, Wang P, Zhang H-M, Liu L-Z, Ye M-X, et al. 1\u03b1,25(OH)\u2082D\u2083 suppresses the migration of ovarian cancer SKOV-3 cells through the Inhibition of Epithelial-Mesenchymal transition. Int J Mol Sci. 2016;17:1285.","journal-title":"Int J Mol Sci"},{"key":"1833_CR26","doi-asserted-by":"publisher","first-page":"14673","DOI":"10.3390\/ijms241914673","volume":"24","author":"MJ Kozie\u0142","year":"2023","unstructured":"Kozie\u0142 MJ, Piastowska-Ciesielska AW, Estrogens. Estrogen receptors and tumor microenvironment in ovarian cancer. Int J Mol Sci. 2023;24:14673.","journal-title":"Int J Mol Sci"},{"key":"1833_CR27","doi-asserted-by":"publisher","first-page":"114304","DOI":"10.1016\/j.biopha.2023.114304","volume":"160","author":"Y Xie","year":"2023","unstructured":"Xie Y, Ren Z, Chen H, Tang H, Zhu M, Lv Z, et al. A novel estrogen-targeted pegylated liposome co-delivery oxaliplatin and Paclitaxel for the treatment of ovarian cancer. Biomed Pharmacother. 2023;160:114304.","journal-title":"Biomed Pharmacother"},{"key":"1833_CR28","doi-asserted-by":"publisher","first-page":"109662","DOI":"10.1016\/j.abb.2023.109662","volume":"743","author":"X Li","year":"2023","unstructured":"Li X, Miao C, Wang L, Liu M, Chang H, Tian B, et al. Estrogen promotes epithelial ovarian cancer cells proliferation via down-regulating expression and activating phosphorylation of PTEN. Arch Biochem Biophys. 2023;743:109662.","journal-title":"Arch Biochem Biophys"},{"key":"1833_CR29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/biom10020237","volume":"10","author":"B Deb","year":"2020","unstructured":"Deb B, Sengupta P, Sambath J, Kumar P. Bioinformatics analysis of global proteomic and phosphoproteomic data sets revealed activation of NEK2 and AURKA in cancers. Biomolecules. 2020;10:237.","journal-title":"Biomolecules"},{"key":"1833_CR30","doi-asserted-by":"publisher","first-page":"13567","DOI":"10.1038\/ncomms13567","volume":"7","author":"GJ Ikink","year":"2016","unstructured":"Ikink GJ, Boer M, Bakker ERM, Hilkens J. IRS4 induces mammary tumorigenesis and confers resistance to HER2-targeted therapy through constitutive PI3K\/AKT-pathway hyperactivation. Nat Commun. 2016;7:13567.","journal-title":"Nat Commun"},{"key":"1833_CR31","doi-asserted-by":"publisher","first-page":"112615","DOI":"10.1016\/j.yexcr.2021.112615","volume":"403","author":"P Hao","year":"2021","unstructured":"Hao P, Huang Y, Peng J, Yu J, Guo X, Bao F, et al. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K\/Akt and Ras-MAPK pathways. Exp Cell Res. 2021;403:112615.","journal-title":"Exp Cell Res"},{"key":"1833_CR32","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","volume":"11","author":"R Liu","year":"2020","unstructured":"Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, et al. PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11:797.","journal-title":"Cell Death Dis"},{"key":"1833_CR33","doi-asserted-by":"publisher","first-page":"e76183","DOI":"10.7554\/eLife.76183","volume":"11","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Xiong X, Zhu Q, Zhang J, Chen S, Wang Y, et al. FER-mediated phosphorylation and PIK3R2 recruitment on IRS4 promotes AKT activation and tumorigenesis in ovarian cancer cells. Elife. 2022;11:e76183.","journal-title":"Elife"},{"key":"1833_CR34","doi-asserted-by":"crossref","unstructured":"Leinonen H, Pham NC, Boyd T, Santoso J, Palczewski K, Vinberg F. Homeostatic plasticity in the retina is associated with maintenance of night vision during retinal degenerative disease. Elife. 2020;9:e59422.","DOI":"10.7554\/eLife.59422"},{"key":"1833_CR35","doi-asserted-by":"crossref","unstructured":"Cr M, Ke O, Jh F. MEK1\/2 inhibitors in the treatment of gynecologic malignancies. Gynecologic oncology [Internet]. 2014 [cited 2025 Jan 12];133. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24434059\/","DOI":"10.1016\/j.ygyno.2014.01.008"},{"key":"1833_CR36","doi-asserted-by":"publisher","first-page":"8178","DOI":"10.3390\/ijms24098178","volume":"24","author":"F Aliqu\u00f2","year":"2023","unstructured":"Aliqu\u00f2 F, Minuti A, Avenoso A, Mandraffino G, Campo GM, Campo S, et al. Endocan promotes Pro-Tumorigenic signaling in lung cancer cells: modulation of cell Proliferation, migration and LncRNAs H19 and HULC expression. Int J Mol Sci. 2023;24:8178.","journal-title":"Int J Mol Sci"},{"key":"1833_CR37","doi-asserted-by":"publisher","first-page":"188496","DOI":"10.1016\/j.bbcan.2020.188496","volume":"1875","author":"K Tyagi","year":"2021","unstructured":"Tyagi K, Roy A. Evaluating the current status of protein kinase C (PKC)-protein kinase D (PKD) signalling axis as a novel therapeutic target in ovarian cancer. Biochim Biophys Acta Rev Cancer. 2021;1875:188496.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1833_CR38","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12885-015-1347-1","volume":"15","author":"K Va\u0161kovi\u010dov\u00e1","year":"2015","unstructured":"Va\u0161kovi\u010dov\u00e1 K, Szabadosov\u00e1 E, \u010cerm\u00e1k V, Gandalovi\u010dov\u00e1 A, Kasalov\u00e1 L, R\u00f6sel D, et al. PKC\u03b1 promotes the mesenchymal to amoeboid transition and increases cancer cell invasiveness. BMC Cancer. 2015;15:326.","journal-title":"BMC Cancer"},{"key":"1833_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1042\/BJ20082377","volume":"424","author":"JP Madigan","year":"2009","unstructured":"Madigan JP, Bodemann BO, Brady DC, Dewar BJ, Keller PJ, Leitges M, et al. Regulation of Rnd3 localization and function by protein kinase C alpha-mediated phosphorylation. Biochem J. 2009;424:153\u201361.","journal-title":"Biochem J"},{"key":"1833_CR40","doi-asserted-by":"publisher","first-page":"e1007394","DOI":"10.1371\/journal.ppat.1007394","volume":"14","author":"M Hulse","year":"2018","unstructured":"Hulse M, Caruso LB, Madzo J, Tan Y, Johnson S, Tempera I. Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1. PLoS Pathog. 2018;14:e1007394.","journal-title":"PLoS Pathog"},{"key":"1833_CR41","doi-asserted-by":"crossref","unstructured":"Zhang X-N, Lam AT, Cheng Q, Courouble VV, Strutzenberg TS, Li J, et al. Discovery of an NAD+ analogue with enhanced specificity for PARP1. Chem Sci. 2022;13:1982\u201391.","DOI":"10.1039\/D1SC06256E"},{"key":"1833_CR42","doi-asserted-by":"publisher","first-page":"12834","DOI":"10.1093\/nar\/gkx1047","volume":"45","author":"L Liu","year":"2017","unstructured":"Liu L, Kong M, Gassman NR, Freudenthal BD, Prasad R, Zhen S, et al. PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1. Nucleic Acids Res. 2017;45:12834\u201347.","journal-title":"Nucleic Acids Res"},{"key":"1833_CR43","doi-asserted-by":"publisher","first-page":"e104542","DOI":"10.15252\/embj.2020104542","volume":"40","author":"Q Chen","year":"2021","unstructured":"Chen Q, Bian C, Wang X, Liu X, Ahmad Kassab M, Yu Y, et al. ADP-ribosylation of histone variant H2AX promotes base excision repair. EMBO J. 2021;40:e104542.","journal-title":"EMBO J"},{"key":"1833_CR44","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.pbiomolbio.2021.01.004","volume":"163","author":"N Pillay","year":"2021","unstructured":"Pillay N, Brady RM, Dey M, Morgan RD, Taylor SS. DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy. Prog Biophys Mol Biol. 2021;163:160\u201370.","journal-title":"Prog Biophys Mol Biol"},{"key":"1833_CR45","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.neo.2019.10.001","volume":"21","author":"A Jim\u00e9nez-Segovia","year":"2019","unstructured":"Jim\u00e9nez-Segovia A, Mota A, Rojo-Sebasti\u00e1n A, Barrocal B, Rynne-Vidal A, Garc\u00eda-Bermejo M-L, et al. Prostaglandin F2\u03b1-induced prostate transmembrane Protein, androgen induced 1 mediates ovarian cancer progression increasing epithelial plasticity. Neoplasia. 2019;21:1073\u201384.","journal-title":"Neoplasia"},{"key":"1833_CR46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.redox.2018.03.016","volume":"17","author":"D Hou","year":"2018","unstructured":"Hou D, Liu Z, Xu X, Liu Q, Zhang X, Kong B, et al. Increased oxidative stress mediates the antitumor effect of PARP Inhibition in ovarian cancer. Redox Biol. 2018;17:99\u2013111.","journal-title":"Redox Biol"},{"key":"1833_CR47","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/s41467-019-09014-2","volume":"10","author":"D Zhang","year":"2019","unstructured":"Zhang D, Hu X, Li J, Liu J, Baks-te Bulte L, Wiersma M, et al. DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD\u2009+\u2009depletion in experimental atrial fibrillation. Nat Commun. 2019;10:1307.","journal-title":"Nat Commun"},{"key":"1833_CR48","doi-asserted-by":"publisher","first-page":"617321","DOI":"10.3389\/fmed.2020.617321","volume":"7","author":"S Ma","year":"2020","unstructured":"Ma S, Zhao X, Zhang C, Sun P, Li Y, Lin X, et al. Ozone exposure induces metabolic disorders and NAD\u2009+\u2009Depletion through PARP1 activation in spinal cord neurons. Front Med (Lausanne). 2020;7:617321.","journal-title":"Front Med (Lausanne)"},{"key":"1833_CR49","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-16-3068","volume":"23","author":"JD Soumerai","year":"2017","unstructured":"Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA, Noy A, et al. The PARP inhibitor veliparib can be safely added to Bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma. Clin Cancer Res. 2017;23:4119\u201326.","journal-title":"Clin Cancer Res"},{"key":"1833_CR50","doi-asserted-by":"publisher","first-page":"e245552","DOI":"10.1001\/jamanetworkopen.2024.5552","volume":"7","author":"PC Schouten","year":"2024","unstructured":"Schouten PC, Schmidt S, Becker K, Thiele H, N\u00fcrnberg P, Richters L, et al. Olaparib addition to maintenance bevacizumab therapy in ovarian carcinoma with BRCA-Like genomic aberrations. JAMA Netw Open. 2024;7:e245552.","journal-title":"JAMA Netw Open"},{"key":"1833_CR51","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-18-0042","volume":"24","author":"G Ison","year":"2018","unstructured":"Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, et al. FDA approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to Platinum-Based chemotherapy. Clin Cancer Res. 2018;24:4066\u201371.","journal-title":"Clin Cancer Res"},{"key":"1833_CR52","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41587-022-01464-2","volume":"41","author":"A Kacen","year":"2023","unstructured":"Kacen A, Javitt A, Kramer MP, Morgenstern D, Tsaban T, Shmueli MD, et al. Post-translational modifications reshape the antigenic landscape of the MHC I immunopeptidome in tumors. Nat Biotechnol. 2023;41:239\u201351.","journal-title":"Nat Biotechnol"},{"key":"1833_CR53","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40164-025-00627-6","volume":"14","author":"Q Hu","year":"2025","unstructured":"Hu Q, Shi Y, Wang H, Bing L, Xu Z. Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy. Exp Hematol Oncol. 2025;14:37.","journal-title":"Exp Hematol Oncol"},{"key":"1833_CR54","doi-asserted-by":"publisher","first-page":"117955492199628","DOI":"10.1177\/1179554921996288","volume":"15","author":"Z Wu","year":"2021","unstructured":"Wu Z, Cui P, Tao H, Zhang S, Ma J, Liu Z, et al. The synergistic effect of PARP inhibitors and immune checkpoint inhibitors. Clin Med Insights Oncol. 2021;15:1179554921996288.","journal-title":"Clin Med Insights Oncol"},{"key":"1833_CR55","doi-asserted-by":"publisher","first-page":"825284","DOI":"10.3389\/fonc.2022.825284","volume":"12","author":"NT Nihira","year":"2022","unstructured":"Nihira NT, Miki Y. Regulation of intrinsic functions of PD-L1 by Post-Translational modification in tumors. Front Oncol. 2022;12:825284.","journal-title":"Front Oncol"},{"key":"1833_CR56","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1158\/0008-5472.CAN-18-1892","volume":"78","author":"J-M Hsu","year":"2018","unstructured":"Hsu J-M, Li C-W, Lai Y-J, Hung M-C. Posttranslational modifications of PD-L1 and their applications in cancer therapy. Cancer Res. 2018;78:6349\u201353.","journal-title":"Cancer Res"},{"key":"1833_CR57","doi-asserted-by":"publisher","first-page":"C933","DOI":"10.1152\/ajpcell.00151.2020","volume":"319","author":"V Sudhahar","year":"2020","unstructured":"Sudhahar V, Okur MN, O\u2019Bryan JP, Minshall RD, Fulton D, Ushio-Fukai M, et al. Caveolin-1 stabilizes ATP7A, a copper transporter for extracellular SOD, in vascular tissue to maintain endothelial function. Am J Physiol Cell Physiol. 2020;319:C933\u201344.","journal-title":"Am J Physiol Cell Physiol"},{"key":"1833_CR58","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1186\/s12935-021-02341-9","volume":"21","author":"Y Chen","year":"2021","unstructured":"Chen Y, Hong H, Wang Q, Li J, Zhang W, Chen T, et al. NEDD4L-induced ubiquitination mediating UBE2T degradation inhibits progression of lung adenocarcinoma via PI3K-AKT signaling. Cancer Cell Int. 2021;21:631.","journal-title":"Cancer Cell Int"},{"key":"1833_CR59","doi-asserted-by":"crossref","unstructured":"Zeng X, Zheng W, Sheng Y, Ma H. UBE2B promotes ovarian cancer growth via promoting RAD18 mediated ZMYM2 monoubiquitination and stabilization. Bioengineered. 2022;13:8000\u201312.","DOI":"10.1080\/21655979.2022.2048991"},{"key":"1833_CR60","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/leu.2016.258","volume":"31","author":"E Malek","year":"2017","unstructured":"Malek E, Abdel-Malek MAY, Jagannathan S, Vad N, Karns R, Jegga AG, et al. Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes bortezomib resistance in multiple myeloma. Leukemia. 2017;31:645\u201353.","journal-title":"Leukemia"},{"key":"1833_CR61","doi-asserted-by":"publisher","first-page":"25260","DOI":"10.1074\/jbc.M311052200","volume":"279","author":"P Li","year":"2004","unstructured":"Li P, Li C, Zhao X, Zhang X, Nicosia SV, Bai W. p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of Cyclin E\/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein\/Skp2 ubiquitin ligase. J Biol Chem. 2004;279:25260\u20137.","journal-title":"J Biol Chem"},{"key":"1833_CR62","first-page":"435","volume":"32","author":"J-S Shin","year":"2008","unstructured":"Shin J-S, Hong S-W, Lee S-LO, Kim T-H, Park I-C, An S-K, et al. Serum starvation induces G1 arrest through suppression of Skp2-CDK2 and CDK4 in SK-OV-3 cells. Int J Oncol. 2008;32:435\u20139.","journal-title":"Int J Oncol"},{"key":"1833_CR63","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1111\/cas.13026","volume":"107","author":"S Kitade","year":"2016","unstructured":"Kitade S, Onoyama I, Kobayashi H, Yagi H, Yoshida S, Kato M, et al. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors. Cancer Sci. 2016;107:1399\u2013405.","journal-title":"Cancer Sci"},{"key":"1833_CR64","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-021-01340-8","volume":"20","author":"F Xu","year":"2021","unstructured":"Xu F, Li J, Ni M, Cheng J, Zhao H, Wang S, et al. FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2. Mol Cancer. 2021;20:45.","journal-title":"Mol Cancer"},{"key":"1833_CR65","doi-asserted-by":"publisher","first-page":"e00088","DOI":"10.1128\/JVI.00088-17","volume":"91","author":"X Zheng","year":"2017","unstructured":"Zheng X, Wang X, Tu F, Wang Q, Fan Z, Gao G. TRIM25 is required for the antiviral activity of zinc finger antiviral protein. J Virol. 2017;91:e00088\u201317.","journal-title":"J Virol"},{"key":"1833_CR66","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41392-021-00580-w","volume":"6","author":"X Zhu","year":"2021","unstructured":"Zhu X, Zhang Y, Luo Q, Wu X, Huang F, Shu T, et al. The deubiquitinase USP11 promotes ovarian cancer chemoresistance by stabilizing BIP. Signal Transduct Target Ther. 2021;6:264.","journal-title":"Signal Transduct Target Ther"},{"key":"1833_CR67","first-page":"3475","volume":"5","author":"K-J Su","year":"2015","unstructured":"Su K-J, Lin C-W, Chen M-K, Yang S-F, Yu Y-L. Effects of EZH2 promoter polymorphisms and methylation status on oral squamous cell carcinoma susceptibility and pathology. Am J Cancer Res. 2015;5:3475\u201384.","journal-title":"Am J Cancer Res"},{"key":"1833_CR68","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ijc.1466","volume":"94","author":"JH Yoon","year":"2001","unstructured":"Yoon JH, Dammann R, Pfeifer GP. Hypermethylation of the CpG Island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer. 2001;94:212\u20137.","journal-title":"Int J Cancer"},{"key":"1833_CR69","doi-asserted-by":"publisher","first-page":"e76787","DOI":"10.1371\/journal.pone.0076787","volume":"8","author":"H Shi","year":"2013","unstructured":"Shi H, Li Y, Wang X, Lu C, Yang L, Gu C, et al. Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis. PLoS ONE. 2013;8:e76787.","journal-title":"PLoS ONE"},{"key":"1833_CR70","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1002\/1878-0261.12545","volume":"13","author":"Z Jing","year":"2019","unstructured":"Jing Z, Bi J, Li Z, Liu X, Li J, Zhu Y, et al. Inhibition of miR-34a\u20105p can rescue disruption of the p53\u2010DAPK axis to suppress progression of clear cell renal cell carcinoma. Mol Oncol. 2019;13:2079\u201397.","journal-title":"Mol Oncol"},{"key":"1833_CR71","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/cdd.2012.136","volume":"20","author":"C-C Chang","year":"2013","unstructured":"Chang C-C, Yang M-H, Lin B-R, Chen S-T, Pan S-H, Hsiao M, et al. CCN2 inhibits lung cancer metastasis through promoting DAPK-dependent Anoikis and inducing EGFR degradation. Cell Death Differ. 2013;20:443\u201355.","journal-title":"Cell Death Differ"},{"key":"1833_CR72","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/nar\/gkv885","volume":"44","author":"Y Wang","year":"2016","unstructured":"Wang Y, Alla V, Goody D, Gupta SK, Spitschak A, Wolkenhauer O, et al. Epigenetic factor EPC1 is a master regulator of DNA damage response by interacting with E2F1 to silence death and activate metastasis-related gene signatures. Nucleic Acids Res. 2016;44:117\u201333.","journal-title":"Nucleic Acids Res"},{"key":"1833_CR73","doi-asserted-by":"crossref","unstructured":"Zhang Y, Charlton J, Karnik R, Beerman I, Smith ZD, Gu H, et al. Targets and genomic constraints of ectopic Dnmt3b expression. Elife. 2018;7:e40757.","DOI":"10.7554\/eLife.40757"},{"key":"1833_CR74","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12943-023-01786-y","volume":"22","author":"J Chen","year":"2023","unstructured":"Chen J, Hong JH, Huang Y, Liu S, Yin J, Deng P, et al. EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer. Mol Cancer. 2023;22:85.","journal-title":"Mol Cancer"},{"key":"1833_CR75","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41419-023-06149-5","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Liu H, Ye M, Jiang M, Chen X, Song G, et al. Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion. Cell Death Dis. 2023;14:624.","journal-title":"Cell Death Dis"},{"key":"1833_CR76","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13148-023-01440-w","volume":"15","author":"SK Terp","year":"2023","unstructured":"Terp SK, Stoico MP, Dybk\u00e6r K, Pedersen IS. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review. Clin Epigenetics. 2023;15:24.","journal-title":"Clin Epigenetics"},{"key":"1833_CR77","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/978-981-15-3266-5_16","volume":"1248","author":"Y Wang","year":"2020","unstructured":"Wang Y, Lu H, Fang C, Xu J. Palmitoylation as a signal for delivery. Adv Exp Med Biol. 2020;1248:399\u2013424.","journal-title":"Adv Exp Med Biol"},{"key":"1833_CR78","doi-asserted-by":"publisher","first-page":"115695","DOI":"10.1016\/j.bcp.2023.115695","volume":"215","author":"CE Villanueva","year":"2023","unstructured":"Villanueva CE, Hagenbuch B. Palmitoylation of solute carriers. Biochem Pharmacol. 2023;215:115695.","journal-title":"Biochem Pharmacol"},{"key":"1833_CR79","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1186\/s12967-023-04611-8","volume":"21","author":"Y Kong","year":"2023","unstructured":"Kong Y, Liu Y, Li X, Rao M, Li D, Ruan X, et al. Palmitoylation landscapes across human cancers reveal a role of palmitoylation in tumorigenesis. J Transl Med. 2023;21:826.","journal-title":"J Transl Med"},{"key":"1833_CR80","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.3390\/cells12182209","volume":"12","author":"M Li","year":"2023","unstructured":"Li M, Zhang L, Chen C-W. Diverse roles of protein palmitoylation in cancer Progression, Immunity, Stemness, and beyond. Cells. 2023;12:2209.","journal-title":"Cells"},{"key":"1833_CR81","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nrm2084","volume":"8","author":"ME Linder","year":"2007","unstructured":"Linder ME, Deschenes RJ. Palmitoylation: policing protein stability and traffic. Nat Rev Mol Cell Biol. 2007;8:74\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1833_CR82","doi-asserted-by":"publisher","first-page":"22076","DOI":"10.1074\/jbc.M803901200","volume":"283","author":"JA Buglino","year":"2008","unstructured":"Buglino JA, Resh MD. Hhat is a Palmitoylacyltransferase with specificity for N-palmitoylation of Sonic Hedgehog. J Biol Chem. 2008;283:22076\u201388.","journal-title":"J Biol Chem"},{"key":"1833_CR83","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/cas.16085","volume":"115","author":"X Zhang","year":"2024","unstructured":"Zhang X, Liao X, Wang M, Liu J, Han J, An D, et al. Inhibition of palmitoyltransferase ZDHHC12 sensitizes ovarian cancer cells to cisplatin through ROS-mediated mechanisms. Cancer Sci. 2024;115:1170\u201383.","journal-title":"Cancer Sci"},{"key":"1833_CR84","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.apsb.2020.03.008","volume":"10","author":"M Yuan","year":"2020","unstructured":"Yuan M, Chen X, Sun Y, Jiang L, Xia Z, Ye K, et al. ZDHHC12-mediated claudin-3 S-palmitoylation determines ovarian cancer progression. Acta Pharm Sin B. 2020;10:1426\u201339.","journal-title":"Acta Pharm Sin B"},{"key":"1833_CR85","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s11427-021-2048-2","volume":"65","author":"X Pei","year":"2022","unstructured":"Pei X, Li K-Y, Shen Y, Li J-T, Lei M-Z, Fang C-Y, et al. Palmitoylation of MDH2 by ZDHHC18 activates mitochondrial respiration and accelerates ovarian cancer growth. Sci China Life Sci. 2022;65:2017\u201330.","journal-title":"Sci China Life Sci"},{"key":"1833_CR86","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.biocel.2017.12.010","volume":"95","author":"X-Y Zhang","year":"2018","unstructured":"Zhang X-Y, Zhang M, Cong Q, Zhang M-X, Zhang M-Y, Lu Y-Y, et al. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy. Int J Biochem Cell Biol. 2018;95:9\u201316.","journal-title":"Int J Biochem Cell Biol"},{"key":"1833_CR87","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1756-9966-31-6","volume":"31","author":"N Wang","year":"2012","unstructured":"Wang N, Zhang H, Yao Q, Wang Y, Dai S, Yang X. TGFBI promoter hypermethylation correlating with Paclitaxel chemoresistance in ovarian cancer. J Exp Clin Cancer Res. 2012;31:6.","journal-title":"J Exp Clin Cancer Res"},{"key":"1833_CR88","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13048-021-00807-y","volume":"14","author":"L-Y Feng","year":"2021","unstructured":"Feng L-Y, Huang Y-Z, Zhang W, Li L. LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer. J Ovarian Res. 2021;14:67.","journal-title":"J Ovarian Res"},{"key":"1833_CR89","first-page":"1083","volume":"56","author":"J Zhao","year":"2020","unstructured":"Zhao J, Xue X, Fu W, Dai L, Jiang Z, Zhong S, et al. Epigenetic activation of FOXF1 confers cancer stem cell properties to cisplatin-resistant non-small cell lung cancer. Int J Oncol. 2020;56:1083\u201392.","journal-title":"Int J Oncol"},{"key":"1833_CR90","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1158\/1541-7786.MCR-13-0480","volume":"12","author":"ZP Lin","year":"2014","unstructured":"Lin ZP, Ratner ES, Whicker ME, Lee Y, Sartorelli AC. Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors. Mol Cancer Res. 2014;12:381\u201393.","journal-title":"Mol Cancer Res"},{"key":"1833_CR91","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","volume":"23","author":"B Weigelt","year":"2017","unstructured":"Weigelt B, Comino-M\u00e9ndez I, de Bruijn I, Tian L, Meisel JL, Garc\u00eda-Murillas I, et al. Diverse BRCA1 and BRCA2 reversion mutations in Circulating Cell-Free DNA of Therapy-Resistant breast or ovarian cancer. Clin Cancer Res. 2017;23:6708\u201320.","journal-title":"Clin Cancer Res"},{"key":"1833_CR92","doi-asserted-by":"publisher","first-page":"e1007277","DOI":"10.1371\/journal.pgen.1007277","volume":"14","author":"T Yasuda","year":"2018","unstructured":"Yasuda T, Kagawa W, Ogi T, Kato TA, Suzuki T, Dohmae N, et al. Novel function of hats and HDACs in homologous recombination through acetylation of human RAD52 at double-strand break sites. PLoS Genet. 2018;14:e1007277.","journal-title":"PLoS Genet"},{"key":"1833_CR93","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.3390\/nu14153206","volume":"14","author":"D Park","year":"2022","unstructured":"Park D, Lim JW, Kim H. \u03b1-Lipoic acid inhibits apoptosis by suppressing the loss of Ku proteins in Helicobacter pylori-Infected human gastric epithelial cells. Nutrients. 2022;14:3206.","journal-title":"Nutrients"},{"key":"1833_CR94","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.molcel.2015.02.024","volume":"58","author":"W Jiang","year":"2015","unstructured":"Jiang W, Crowe JL, Liu X, Nakajima S, Wang Y, Li C, et al. Differential phosphorylation of DNA-PKcs regulates the interplay between end-processing and end-ligation during non-homologous end-joining. Mol Cell. 2015;58:172\u201385.","journal-title":"Mol Cell"},{"key":"1833_CR95","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1093\/nar\/gkr1242","volume":"40","author":"B Renouf","year":"2012","unstructured":"Renouf B, Soret C, Saandi T, Delalande F, Martin E, Vanier M, et al. Cdx2 Homeoprotein inhibits non-homologous end joining in colon cancer but not in leukemia cells. Nucleic Acids Res. 2012;40:3456\u201369.","journal-title":"Nucleic Acids Res"},{"key":"1833_CR96","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41589-024-01683-5","volume":"21","author":"Z Peng","year":"2025","unstructured":"Peng Z, Fang W, Wu B, He M, Li S, Wei J, et al. Targeting Smurf1 to block PDK1-Akt signaling in KRAS-mutated colorectal cancer. Nat Chem Biol. 2025;21:59\u201370.","journal-title":"Nat Chem Biol"},{"key":"1833_CR97","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","volume":"18","author":"M Schapira","year":"2019","unstructured":"Schapira M, Calabrese MF, Bullock AN, Crews CM. Targeted protein degradation: expanding the toolbox. Nat Rev Drug Discov. 2019;18:949\u201363.","journal-title":"Nat Rev Drug Discov"},{"key":"1833_CR98","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41419-023-06379-7","volume":"14","author":"J Feng","year":"2023","unstructured":"Feng J, Ye S, Hai B, Lou Y, Duan M, Guo P, et al. RNF115\/BCA2 deficiency alleviated acute liver injury in mice by promoting autophagy and inhibiting inflammatory response. Cell Death Dis. 2023;14:855.","journal-title":"Cell Death Dis"},{"key":"1833_CR99","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1136\/ijgc-2021-002727","volume":"31","author":"C Marchetti","year":"2021","unstructured":"Marchetti C, Tudisco R, Salutari V, Pietragalla A, Scambia G, Fagotti A. Neoadjuvant chemoteraphy in unresectable ovarian cancer with Olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial). Int J Gynecol Cancer. 2021;31:1175\u20138.","journal-title":"Int J Gynecol Cancer"},{"key":"1833_CR100","doi-asserted-by":"publisher","first-page":"577869","DOI":"10.3389\/fimmu.2020.577869","volume":"11","author":"C Yang","year":"2020","unstructured":"Yang C, Xia B-R, Zhang Z-C, Zhang Y-J, Lou G, Jin W-L. Immunotherapy for ovarian cancer: Adjuvant, Combination, and neoadjuvant. Front Immunol. 2020;11:577869.","journal-title":"Front Immunol"},{"key":"1833_CR101","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/ijc.33918","volume":"150","author":"C Zong","year":"2022","unstructured":"Zong C, Zhu T, He J, Huang R, Jia R, Shen J. PARP mediated DNA damage response, genomic stability and immune responses. Int J Cancer. 2022;150:1745\u201359.","journal-title":"Int J Cancer"},{"key":"1833_CR102","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/pharmaceutics14010150","volume":"14","author":"SV Hartimath","year":"2022","unstructured":"Hartimath SV, Ramasamy B, Xuan TY, Rong TJ, Khanapur S, Cheng P, et al. Granzyme B PET imaging in response to in situ vaccine therapy combined with \u03b1PD1 in a murine colon cancer model. Pharmaceutics. 2022;14:150.","journal-title":"Pharmaceutics"},{"key":"1833_CR103","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","volume":"3","author":"T Higuchi","year":"2015","unstructured":"Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, et al. CTLA-4 Blockade synergizes therapeutically with PARP Inhibition in BRCA1-Deficient ovarian cancer. Cancer Immunol Res. 2015;3:1257\u201368.","journal-title":"Cancer Immunol Res"},{"key":"1833_CR104","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","volume":"26","author":"EJ Lampert","year":"2020","unstructured":"Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, et al. Combination of PARP inhibitor Olaparib, and PD-L1 inhibitor Durvalumab, in recurrent ovarian cancer: a Proof-of-Concept phase II study. Clin Cancer Res. 2020;26:4268\u201379.","journal-title":"Clin Cancer Res"},{"key":"1833_CR105","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.3390\/ijms25105067","volume":"25","author":"M Vorderbruggen","year":"2024","unstructured":"Vorderbruggen M, Vel\u00e1zquez-Mart\u00ednez CA, Natarajan A, Karpf AR. PROTACs in ovarian cancer: current advancements and future perspectives. Int J Mol Sci. 2024;25:5067.","journal-title":"Int J Mol Sci"},{"key":"1833_CR106","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","volume":"181","author":"GM Burslem","year":"2020","unstructured":"Burslem GM, Crews CM. Proteolysis-Targeting chimeras as therapeutics and tools for biological discovery. Cell. 2020;181:102\u201314.","journal-title":"Cell"},{"key":"1833_CR107","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1039\/D1CB00011J","volume":"2","author":"MJ Bond","year":"2021","unstructured":"Bond MJ, Crews CM. Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation. RSC Chem Biol. 2021;2:725\u201342.","journal-title":"RSC Chem Biol"},{"key":"1833_CR108","doi-asserted-by":"crossref","unstructured":"C YZXXRSXZ. W, B J, Development of the nonreceptor tyrosine kinase FER-targeting PROTACs as a potential strategy for antagonizing ovarian cancer cell motility and invasiveness. The Journal of biological chemistry [Internet]. 2023 [cited 2024 Jun 20];299. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37196766\/","DOI":"10.1016\/j.jbc.2023.104825"},{"key":"1833_CR109","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1038\/s41388-020-1336-y","volume":"39","author":"S Khan","year":"2020","unstructured":"Khan S, He Y, Zhang X, Yuan Y, Pu S, Kong Q, et al. PROteolysis targeting chimeras (PROTACs) as emerging anticancer therapeutics. Oncogene. 2020;39:4909\u201324.","journal-title":"Oncogene"},{"key":"1833_CR110","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495\u2013505.","journal-title":"N Engl J Med"},{"key":"1833_CR111","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382\u201392.","journal-title":"N Engl J Med"},{"key":"1833_CR112","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in Platinum-Sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154\u201364.","journal-title":"N Engl J Med"},{"key":"1833_CR113","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:636\u201348.","journal-title":"Lancet Oncol"},{"key":"1833_CR114","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18:75\u201387.","journal-title":"Lancet Oncol"},{"key":"1833_CR115","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949\u201361.","journal-title":"Lancet"},{"key":"1833_CR116","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00428-005-0091-3","volume":"448","author":"Y-L Choi","year":"2006","unstructured":"Choi Y-L, Kang SY, Shin YK, Choi JS, Kim SH, Lee S-J, et al. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Arch. 2006;448:331\u20136.","journal-title":"Virchows Arch"},{"key":"1833_CR117","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1159\/000484245","volume":"83","author":"H Wang","year":"2018","unstructured":"Wang H, Cui M, Zhang S, He J, Song L, Chen Y. Relationship between RAS association domain family protein 1A promoter methylation and the clinicopathological characteristics in patients with ovarian cancer: A systematic Meta-Analysis. Gynecol Obstet Invest. 2018;83:349\u201357.","journal-title":"Gynecol Obstet Invest"},{"key":"1833_CR118","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","volume":"27","author":"M Moschetta","year":"2016","unstructured":"Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016;27:1449\u201355.","journal-title":"Ann Oncol"},{"key":"1833_CR119","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-22-3328","volume":"29","author":"F Blanc-Durand","year":"2023","unstructured":"Blanc-Durand F, Tang R, Pommier M, Nashvi M, Cotteret S, Genestie C, et al. Clinical relevance of BRCA1 promoter methylation testing in patients with ovarian cancer. Clin Cancer Res. 2023;29:3124\u20139.","journal-title":"Clin Cancer Res"},{"key":"1833_CR120","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/ijc.32984","volume":"147","author":"A Singh","year":"2020","unstructured":"Singh A, Gupta S, Badarukhiya JA, Sachan M. Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer. Int J Cancer. 2020;147:1740\u201352.","journal-title":"Int J Cancer"},{"key":"1833_CR121","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ygyno.2008.07.036","volume":"111","author":"Q Feng","year":"2008","unstructured":"Feng Q, Deftereos G, Hawes SE, Stern JE, Willner JB, Swisher EM, et al. DNA hypermethylation, Her-2\/neu overexpression and p53 mutations in ovarian carcinoma. Gynecol Oncol. 2008;111:320\u20139.","journal-title":"Gynecol Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01833-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01833-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01833-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:05:06Z","timestamp":1762877106000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-025-01833-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":121,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1833"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01833-w","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and agreed to the published version of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"251"}}